Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hashimoto's study probes hidden inflammation and reverse T3 levels

NCT ID NCT07510750

Knowledge-focused Sponsor: Ankara City Hospital Bilkent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study from Ankara City Hospital Bilkent examined 179 people with Hashimoto's thyroiditis, an autoimmune condition that affects the thyroid. Researchers compared levels of reverse T3, a little-studied thyroid hormone, and inflammation markers in patients who were or were not taking thyroid hormone replacement. The goal was to better understand systemic inflammation in Hashimoto's and how treatment might affect these markers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

179 people

The number who actually took part.

Started

Aug 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy Control

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Between the ages of 18-50, anti-TPO negative, normal thyroid hormone levels, not pregnant or breastfeeding, no chronic disease or acute infection. Exclusion Criteria: * Patients with positive anti-TPO results, TSH, sT4, and sT3 hormone levels outside the reference range, pregnant or breastfeeding patients, those with chronic diseases, those with signs of acute infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hashimoto thyroiditis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hashimoto thyroiditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hashimoto thyroiditis

Contacts and locations

Locations

  • Ankara Bilkent City Hospital

    Ankara, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.